Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Colorectal Cancer | Research

Identification and clinical validation of key genes as the potential biomarkers in colorectal adenoma

Authors: Bangting Wang, Jiting Zhang, Xin Wang, Lili Zhao, Yan Wang, Zhining Fan, Li Liu, Wenqing Gao

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Colorectal cancer (CRC), ranking third in cancer prevalence and second in mortality worldwide, is mainly derived from colorectal adenoma (CRA). CRA is a common benign disease in the intestine with rapidly increasing incidence and malignant potential. Therefore, this study aimed to recognize significant biomarkers and original pathogenesis in CRA.

Methods

Transcriptome data of GSE8671, GSE37364, and GSE15960 were downloaded from the Gene Expression Omnibus (GEO) datasets, and differentially expressed genes (DEGs) were screened. Functional pathways enrichment, protein–protein interaction (PPI) network, stem-correlation analysis, CIBERSORT, risk score and survival analyses were performed. RT-qPCR and immunohistochemical staining were applied to verify our results. 

Results

Screening for significant DEGs in each dataset, we identified 230 robust DEGs, including 127 upregulated and 103 downregulated genes. Functional pathways enrichment showed that these DEGs were distinctly enriched in various tumor-associated pathways, such as growth factor activity, extracellular structure organization, neutrophil activation, and inflammatory response. We filtered out two hub genes via STRING and Modules analysis, including CA2 and HSD11B2. Stem-correlation analysis displayed that hub genes were negatively associated with stem-related genes (Olfm4, CD44, CCND1 and MYC). The CIBERSORT algorithm indicated that Macrophage2, activated mast cells, and Neutrophils promoted CRA progression through inflammation. Survival analysis showed that CA2 and HSD11B2 were positively associated with survival outcomes in CRC.

Conclusion

Our study has successfully identified the critical role of two core genes in the development and oncogenesis of CRA, which provides novel insight into the underlying pathogenesis, potential biomarkers and therapeutic targets.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M. Colorectal cancer. Lancet (London, England). 2019;394(10207):1467–80.CrossRef Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M. Colorectal cancer. Lancet (London, England). 2019;394(10207):1467–80.CrossRef
2.
go back to reference Kanth P, Inadomi J. Screening and prevention of colorectal cancer. BMJ (Clinical Research Ed). 2021;374:n1855. Kanth P, Inadomi J. Screening and prevention of colorectal cancer. BMJ (Clinical Research Ed). 2021;374:n1855.
3.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2018;68(6):394–424.CrossRef
4.
go back to reference Wu Y, Li Y, Giovannucci E. Potential Impact of Time Trend of Lifestyle Risk Factors on Burden of Major Gastrointestinal Cancers in China. Gastroenterology. 2021;161(6):1830-1841.e1838.CrossRef Wu Y, Li Y, Giovannucci E. Potential Impact of Time Trend of Lifestyle Risk Factors on Burden of Major Gastrointestinal Cancers in China. Gastroenterology. 2021;161(6):1830-1841.e1838.CrossRef
5.
go back to reference Akimoto N, Ugai T, Zhong R, Hamada T, Fujiyoshi K, Giannakis M, Wu K, Cao Y, Ng K, Ogino S. Rising incidence of early-onset colorectal cancer - a call to action. Nat Rev Clin Oncol. 2021;18(4):230–43.CrossRef Akimoto N, Ugai T, Zhong R, Hamada T, Fujiyoshi K, Giannakis M, Wu K, Cao Y, Ng K, Ogino S. Rising incidence of early-onset colorectal cancer - a call to action. Nat Rev Clin Oncol. 2021;18(4):230–43.CrossRef
6.
go back to reference Smit WL, Spaan CN, Johannes de Boer R, Ramesh P, Martins Garcia T, Meijer BJ, Vermeulen JLM, Lezzerini M, MacInnes AW, Koster J, et al. Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity. Proc Natl Acad Sci U S A. 2020;117(41):25560–70.CrossRef Smit WL, Spaan CN, Johannes de Boer R, Ramesh P, Martins Garcia T, Meijer BJ, Vermeulen JLM, Lezzerini M, MacInnes AW, Koster J, et al. Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity. Proc Natl Acad Sci U S A. 2020;117(41):25560–70.CrossRef
7.
go back to reference Matas J, Kohrn B, Fredrickson J, Carter K, Yu M, Wang T, Gui X, Soussi T, Moreno V, Grady W, et al. Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon. Can Res. 2022;82(8):1492–502.CrossRef Matas J, Kohrn B, Fredrickson J, Carter K, Yu M, Wang T, Gui X, Soussi T, Moreno V, Grady W, et al. Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon. Can Res. 2022;82(8):1492–502.CrossRef
8.
go back to reference Vacante M, Ciuni R, Basile F, Biondi A. Gut Microbiota and Colorectal Cancer Development: A Closer Look to the Adenoma-Carcinoma Sequence. Biomedicines. 2020;8(11):489.CrossRef Vacante M, Ciuni R, Basile F, Biondi A. Gut Microbiota and Colorectal Cancer Development: A Closer Look to the Adenoma-Carcinoma Sequence. Biomedicines. 2020;8(11):489.CrossRef
9.
go back to reference Hisabe T, Hirai F, Matsui T. Development and progression of colorectal cancer based on follow-up analysis. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society. 2014. p. 73–7. Hisabe T, Hirai F, Matsui T. Development and progression of colorectal cancer based on follow-up analysis. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society. 2014. p. 73–7.
10.
go back to reference Hossain M, Karuniawati H, Jairoun A, Urbi Z, Ooi J, John A, Lim Y, Kibria K, Mohiuddin A, Ming L, et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers. 2022;14(7):1732.CrossRef Hossain M, Karuniawati H, Jairoun A, Urbi Z, Ooi J, John A, Lim Y, Kibria K, Mohiuddin A, Ming L, et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers. 2022;14(7):1732.CrossRef
11.
go back to reference Li J, You L, Xu Z, Bai H, Fei X, Yang J, Li Q, Qian S, Lin S, Tang M, et al. Healthy lifestyle and the risk of conventional adenomas and serrated polyps: Findings from a large colonoscopy screening population. Int J Cancer. 2022;151(1):67–76.CrossRef Li J, You L, Xu Z, Bai H, Fei X, Yang J, Li Q, Qian S, Lin S, Tang M, et al. Healthy lifestyle and the risk of conventional adenomas and serrated polyps: Findings from a large colonoscopy screening population. Int J Cancer. 2022;151(1):67–76.CrossRef
12.
go back to reference Gao Q, Chen H, Sheng J, Zheng P, Yu C, Jiang B, Fang J. The first year follow-up after colorectal adenoma polypectomy is important: a multiple-center study in symptomatic hospital-based individuals in China. Front Med China. 2010;4(4):436–42.CrossRef Gao Q, Chen H, Sheng J, Zheng P, Yu C, Jiang B, Fang J. The first year follow-up after colorectal adenoma polypectomy is important: a multiple-center study in symptomatic hospital-based individuals in China. Front Med China. 2010;4(4):436–42.CrossRef
13.
go back to reference Tate DJ, Desomer L, Klein A, Brown G, Hourigan LF, Lee EY, Moss A, Ormonde D, Raftopoulos S, Singh R, et al. Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence tool. Gastrointest Endosc. 2017;85(3):647-656e646.CrossRef Tate DJ, Desomer L, Klein A, Brown G, Hourigan LF, Lee EY, Moss A, Ormonde D, Raftopoulos S, Singh R, et al. Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence tool. Gastrointest Endosc. 2017;85(3):647-656e646.CrossRef
14.
go back to reference Sabates-Bellver J, Van der Flier L, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski M, Bujnicki J, Menigatti M, et al. Transcriptome profile of human colorectal adenomas. MCR. 2007;5(12):1263–75.CrossRef Sabates-Bellver J, Van der Flier L, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski M, Bujnicki J, Menigatti M, et al. Transcriptome profile of human colorectal adenomas. MCR. 2007;5(12):1263–75.CrossRef
15.
go back to reference Galamb O, Spisák S, Sipos F, Tóth K, Solymosi N, Wichmann B, Krenács T, Valcz G, Tulassay Z, Molnár B. Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer. 2010;102(4):765–73.CrossRef Galamb O, Spisák S, Sipos F, Tóth K, Solymosi N, Wichmann B, Krenács T, Valcz G, Tulassay Z, Molnár B. Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer. 2010;102(4):765–73.CrossRef
16.
go back to reference Molnár B, Galamb O, Péterfia B, Wichmann B, Csabai I, Bodor A, Kalmár A, Szigeti K, Barták B, Nagy Z, et al. Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations. BMC Cancer. 2018;18(1):695.CrossRef Molnár B, Galamb O, Péterfia B, Wichmann B, Csabai I, Bodor A, Kalmár A, Szigeti K, Barták B, Nagy Z, et al. Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations. BMC Cancer. 2018;18(1):695.CrossRef
17.
go back to reference Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999;27(1):29–34.CrossRef Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999;27(1):29–34.CrossRef
18.
go back to reference Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M: KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:587–92. Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M: KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:587–92.
19.
go back to reference Wang B, Wang X, Tseng Y, Huang M, Luo F, Zhang J, Liu J. Distinguishing colorectal adenoma from hyperplastic polyp by WNT2 expression. J Clin Lab Anal. 2021;35(10):e23961.CrossRef Wang B, Wang X, Tseng Y, Huang M, Luo F, Zhang J, Liu J. Distinguishing colorectal adenoma from hyperplastic polyp by WNT2 expression. J Clin Lab Anal. 2021;35(10):e23961.CrossRef
20.
go back to reference Liu X, Li X, Zheng P, Yang W. DAX1 promotes cervical cancer cell growth and tumorigenicity through activation of Wnt/β-catenin pathway via GSK3β. Cell Death Dis. 2018;9(3):339.CrossRef Liu X, Li X, Zheng P, Yang W. DAX1 promotes cervical cancer cell growth and tumorigenicity through activation of Wnt/β-catenin pathway via GSK3β. Cell Death Dis. 2018;9(3):339.CrossRef
21.
go back to reference Nakamura F, Sato Y, Okamoto K, Fujino Y, Mitsui Y, Kagemoto K, Kawaguchi T, Miyamoto H, Muguruma N, Sonoda T, et al. Colorectal carcinoma occurring via the adenoma-carcinoma pathway in patients with serrated polyposis syndrome. J Gastroenterol. 2022;57(4):286–99.CrossRef Nakamura F, Sato Y, Okamoto K, Fujino Y, Mitsui Y, Kagemoto K, Kawaguchi T, Miyamoto H, Muguruma N, Sonoda T, et al. Colorectal carcinoma occurring via the adenoma-carcinoma pathway in patients with serrated polyposis syndrome. J Gastroenterol. 2022;57(4):286–99.CrossRef
22.
go back to reference Mukherjee S, Luedeke D, McCoy L, Iwafuchi M, Zorn A. SOX transcription factors direct TCF-independent WNT/β-catenin responsive transcription to govern cell fate in human pluripotent stem cells. Cell Rep. 2022;40(8):111247.CrossRef Mukherjee S, Luedeke D, McCoy L, Iwafuchi M, Zorn A. SOX transcription factors direct TCF-independent WNT/β-catenin responsive transcription to govern cell fate in human pluripotent stem cells. Cell Rep. 2022;40(8):111247.CrossRef
23.
go back to reference Langiu M, Palacios-Acedo A, Crescence L, Mege D, Dubois C, Panicot-Dubois L. Neutrophils, Cancer and Thrombosis: The New Bermuda Triangle in Cancer Research. Int J Mol Sci. 2022;23(3):1257.CrossRef Langiu M, Palacios-Acedo A, Crescence L, Mege D, Dubois C, Panicot-Dubois L. Neutrophils, Cancer and Thrombosis: The New Bermuda Triangle in Cancer Research. Int J Mol Sci. 2022;23(3):1257.CrossRef
24.
go back to reference Xie D, Pei Q, Li J, Wan X, Ye T. Emerging Role of E2F Family in Cancer Stem Cells. Front Oncol. 2021;11:723137.CrossRef Xie D, Pei Q, Li J, Wan X, Ye T. Emerging Role of E2F Family in Cancer Stem Cells. Front Oncol. 2021;11:723137.CrossRef
25.
go back to reference Donati G, Amati B. MYC and therapy resistance in cancer: risks and opportunities. Molecular oncology. 2022;16(21):3828–54.CrossRef Donati G, Amati B. MYC and therapy resistance in cancer: risks and opportunities. Molecular oncology. 2022;16(21):3828–54.CrossRef
26.
go back to reference Pouysségur J, Marchiq I, Parks S, Durivault J, Ždralević M, Vucetic M. “Warburg effect” controls tumor growth, bacterial, viral infections and immunity - Genetic deconstruction and therapeutic perspectives. Semin Cancer Biol. 2022;86:334–46.CrossRef Pouysségur J, Marchiq I, Parks S, Durivault J, Ždralević M, Vucetic M. “Warburg effect” controls tumor growth, bacterial, viral infections and immunity - Genetic deconstruction and therapeutic perspectives. Semin Cancer Biol. 2022;86:334–46.CrossRef
27.
go back to reference Perl A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci. 2015;1346(1):33–44.CrossRef Perl A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci. 2015;1346(1):33–44.CrossRef
28.
go back to reference Zhao K, Schäfer A, Zhang Z, Elsässer K, Culmsee C, Zhong L, Pagenstecher A, Nimsky C, Bartsch J. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells. Int J Mol Sci. 2021;23(1):157.CrossRef Zhao K, Schäfer A, Zhang Z, Elsässer K, Culmsee C, Zhong L, Pagenstecher A, Nimsky C, Bartsch J. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells. Int J Mol Sci. 2021;23(1):157.CrossRef
29.
go back to reference Cabaleiro-Lago C, Lundqvist M. The Effect of Nanoparticles on the Structure and Enzymatic Activity of Human Carbonic Anhydrase I and II. Molecules (Basel, Switzerland). 2020;25(19):4405.CrossRef Cabaleiro-Lago C, Lundqvist M. The Effect of Nanoparticles on the Structure and Enzymatic Activity of Human Carbonic Anhydrase I and II. Molecules (Basel, Switzerland). 2020;25(19):4405.CrossRef
30.
go back to reference Zhang H, Zhuo C, Zhou D, Zhang F, Chen M, Xu S, Chen Z. Association between the expression of carbonic anhydrase II and clinicopathological features of hepatocellular carcinoma. Oncol Lett. 2019;17(6):5721–8. Zhang H, Zhuo C, Zhou D, Zhang F, Chen M, Xu S, Chen Z. Association between the expression of carbonic anhydrase II and clinicopathological features of hepatocellular carcinoma. Oncol Lett. 2019;17(6):5721–8.
31.
go back to reference Hu X, Huang Z, Liao Z, He C, Fang X. Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients. Int J Clin Exp Pathol. 2014;7(10):6716–24. Hu X, Huang Z, Liao Z, He C, Fang X. Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients. Int J Clin Exp Pathol. 2014;7(10):6716–24.
32.
go back to reference Li X, Xie H, Lei S, Cao H, Meng T, Hu Y. Reduction of CAII Expression in Gastric Cancer: Correlation with Invasion and Metastasis. Chin J Cancer Res. 2012;24(3):196–200.CrossRef Li X, Xie H, Lei S, Cao H, Meng T, Hu Y. Reduction of CAII Expression in Gastric Cancer: Correlation with Invasion and Metastasis. Chin J Cancer Res. 2012;24(3):196–200.CrossRef
33.
go back to reference Zhang C, Wang H, Chen Z, Zhuang L, Xu L, Ning Z, Zhu Z, Wang P, Meng Z. Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. Carcinogenesis. 2018;39(4):562–70.CrossRef Zhang C, Wang H, Chen Z, Zhuang L, Xu L, Ning Z, Zhu Z, Wang P, Meng Z. Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma. Carcinogenesis. 2018;39(4):562–70.CrossRef
34.
go back to reference Konstantakou P, Mastorakos G, Vrachnis N, Tomlinson J, Valsamakis G. Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond. J Matern Fetal Neonatal Med. 2017;30(3):284–93.CrossRef Konstantakou P, Mastorakos G, Vrachnis N, Tomlinson J, Valsamakis G. Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond. J Matern Fetal Neonatal Med. 2017;30(3):284–93.CrossRef
35.
go back to reference Nedungadi D, Ryan N, Anderson K, Lamenza F, Jordanides P, Swingler M, Rakotondraibe L, Riedl K, Iwenofu H, Oghumu S. Modulation of the oral glucocorticoid system during black raspberry mediated oral cancer chemoprevention. Carcinogenesis. 2022;43(1):28–39.CrossRef Nedungadi D, Ryan N, Anderson K, Lamenza F, Jordanides P, Swingler M, Rakotondraibe L, Riedl K, Iwenofu H, Oghumu S. Modulation of the oral glucocorticoid system during black raspberry mediated oral cancer chemoprevention. Carcinogenesis. 2022;43(1):28–39.CrossRef
36.
go back to reference Chen J, Liu Q, Du P, Ning D, Mo J, Zhu H, Wang C, Ge Q, Cheng Q, Zhang X, et al. Type-2 11β-hydroxysteroid dehydrogenase promotes the metastasis of colorectal cancer via the Fgfbp1-AKT pathway. Am J Cancer Res. 2020;10(2):662–73. Chen J, Liu Q, Du P, Ning D, Mo J, Zhu H, Wang C, Ge Q, Cheng Q, Zhang X, et al. Type-2 11β-hydroxysteroid dehydrogenase promotes the metastasis of colorectal cancer via the Fgfbp1-AKT pathway. Am J Cancer Res. 2020;10(2):662–73.
Metadata
Title
Identification and clinical validation of key genes as the potential biomarkers in colorectal adenoma
Authors
Bangting Wang
Jiting Zhang
Xin Wang
Lili Zhao
Yan Wang
Zhining Fan
Li Liu
Wenqing Gao
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-10422-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine